Press Releases Year None2022202120202019201820172016 Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201 August 10, 2022 PDF Version View HTML Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast August 8, 2022 PDF Version View HTML Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review August 1, 2022 PDF Version View HTML Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference June 13, 2022 PDF Version View HTML Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors June 10, 2022 PDF Version View HTML Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel June 2, 2022 PDF Version View HTML Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference June 1, 2022 PDF Version View HTML Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201 June 1, 2022 PDF Version View HTML Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference May 17, 2022 PDF Version View HTML Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update May 10, 2022 PDF Version View HTML Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 25
